Verastem Oncology (VSTM) — RAMP 201J, AVMAPKI FAKZYNJA launch and VS-7375: how solid is the 2026–2027 roadmap?

1. Executive summary — what just changed with this earnings release

Verastem has now delivered its first full commercial year for AVMAPKI FAKZYNJA CO-PACK in KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). Net product revenue reached $17.5M in Q4 2025 and $30.9M for the full year, following accelerated FDA approval in May 2025. At the same time, the company reported non-GAAP adjusted net loss of $39.8M, or $0.48 per share, in Q4, reflecting heavy launch and pipeline investment, while cash and investments stood at $205M, or $234.4M pro-forma after warrant exercises, supporting a runway into the first half of 2027.

On the clinical side, the update puts a bright spotlight on Japan RAMP 201J bridging data. In 16 patients with recurrent LGSOC, gehabt a confirmed overall response rate (ORR) of 38%, with 57% ORR and 100% disease control in KRAS-mutant patients and 22% ORR in KRAS wild-type disease. Safety looked clean, with no discontinuations due to adverse events and exposures comparable to the global RAMP 201 study.

The tension in the story comes from the NCCN decision at the end of February: the guidelines did not extend the recommendation to KRAS wild-type LGSOC, even though prescriber adoption and reimbursement in real-world practice appear broader. Management continues to guide that the LGSOC franchise could become cash self-sustaining by the second half of 2026, but the ultimate validation still depends on RAMP 301, with topline readout targeted for mid-2027.

In parallel, VS-7375, the oral KRAS G12D ON/OFF inhibitor, is transitioning from simple dose escalation to a more clearly registration-oriented plan: the company cleared 900 mg QD monotherapy with no dose-limiting toxicities and is now escalating to 1200 mg, while the FDA has directed Verastem to separate disease-specific Phase 2, registration-style trials in second-line pancreatic cancer, second/third-line NSCLC and later-line colorectal cancer in combination with cetuximab.

2. LGSOC franchise — Japan RAMP 201J vs guidelines and real-world practice

AVMAPKI FAKZYNJA CO-PACK is now the first and only targeted therapy specifically approved for KRAS-mutant recurrent LGSOC, an ultra-orphan population with high unmet need and historically limited effective options. The U.S. launch has focused on early recurrence — positioning the combination as a preferred option at the first or subsequent relapse, rather than a late salvage line.

The RAMP 201J bridging study in Japan is important because it tests whether pharmacokinetics, safety and activity in Japanese patients are consistent with the global RAMP 201 results. With only 16 patients enrolled, it is still a small dataset, but the signal is notable:

• Confirmed ORR 38% (6/16) in the overall population, median follow-up around 10 months.
• KRAS-mutant recurrent LGSOC: ORR 57% (4/7), disease control rate (DCR) 100% (7/7).
• KRAS wild-type recurrent LGSOC: ORR 22% (2/9), DCR 89% (8/9).
• No discontinuations due to adverse events, and steady-state exposures comparable to RAMP 201.

From a regulatory and pricing perspective, this provides a reasonable basis for Verastem to seek a conditional approval in Japan, using the RAMP 201J data as a formal bridge to the global experience. It also supports the core thesis that the combination has activity in both KRAS-mutant and wild-type LGSOC, even though response rates are clearly higher in the mutant population.

The friction arrives on the guideline side. The latest NCCN update for ovarian cancer maintained a category 2A recommendation for avutometinib + defactinib in KRAS-mutant recurrent LGSOC, but did not extend the recommendation to KRAS wild-type disease. This is viewed as a disappointment for a subgroup that currently has no targeted, FDA-approved option specific to their biology.

Interestingly, the company reports that payers are broadly reimbursing AVMAPKI FAKZYNJA CO-PACK regardless of KRAS status, with pushback mostly limited to non-ovarian off-label uses. That creates a fairly unusual gap between formal guidelines and real-world coverage: prescriber and payer behavior seems more permissive than the written guideline language would suggest.

For the next 18–24 months, the trajectory of the LGSOC franchise will likely depend on three moving pieces:

• The pace of prescriber onboarding beyond the nearly 300 current CO-PACK prescribers, and depth of use in top accounts.
• Durability and breadth of response data from longer-term RAMP 201 follow-up and RAMP 201J, including KRAS wild-type outcomes.
• Whether evolving evidence can eventually convince guideline committees to take a broader view of patient selection.

3. Financial profile — burn, leverage and how far the current cash can go

The Q4 2025 numbers confirm that Verastem is firmly in the “investing to scale” phase. Revenue is fully driven by AVMAPKI FAKZYNJA CO-PACK, while operating expenses include a full commercial infrastructure plus R&D for both the LGSOC program and VS-7375.

3.1 Key Q4 2025 and full-year figures

• Q4 2025 net product revenue: $17.5M (vs zero in Q4 2024).
• Full-year 2025 net product revenue: $30.9M (vs zero in 2024; 2024 included a one-time $10M COPIKTRA milestone).
• Q4 total operating expenses: $59.0M, including cost of sales, R&D and SG&A.
• Q4 GAAP net loss: $32.9M, or $0.39 per basic share.
• Q4 non-GAAP adjusted net loss: $39.8M, or $0.48 per basic share.
• Full-year 2025 non-GAAP adjusted net loss: $163.1M, or $2.35 per basic share.

The non-GAAP loss is higher than the GAAP loss in Q4 because GAAP results benefit from non-cash fair value changes in warrants and notes. From a cash standpoint, the relevant lens is still “how much does it cost to run the LGSOC franchise and the pipeline each quarter”.

On the balance sheet, Verastem ended 2025 with $205M in cash, cash equivalents and investments. Including the January 2026 warrant exercises, pro-forma year-end cash is $234.4M. Management states this should fund operations into 1H 2027, assuming the current burn profile and ramp trajectory.

This runway is explicitly designed to bridge the company to the planned RAMP 301 topline readout in mid-2027, while continuing to invest in VS-7375 and other programs. The trade-off is clear: the company is front-loading spending today to try to emerge in 2027 with a validated LGSOC franchise and at least one clearly de-risked KRAS G12D asset in later-line solid tumors.

4. VS-7375 — can KRAS G12D become a second value pillar?

The update on VS-7375 is one of the more strategic pieces in the press release. Verastem and partner GenFleet have already shared promising efficacy data in PDAC and NSCLC with GFH375 in China, including high response rates at the recommended Phase 2 dose. The new element now is how the U.S. program is being guided by the FDA.

After clearing 400, 600 and now 900 mg QD monotherapy without dose-limiting toxicities, and showing exposures that cover the range associated with maximal preclinical anti-tumor activity, the company is moving dose escalation to 1200 mg QD. In parallel, the combination with cetuximab has cleared 600 mg QD with no DLTs, and higher doses are under evaluation.

Based on recent FDA feedback, the Phase 1/2 protocol is being amended to carve out separate, registration-style Phase 2 expansions in:

• Second-line PDAC (monotherapy),
• Second/third-line NSCLC (monotherapy),
• Later-line colorectal cancer in combination with cetuximab.

This is important because it shifts VS-7375 from a pure dose-finding exercise to a program explicitly oriented toward potential accelerated or registrational paths. Combined with GenFleet’s ongoing Phase 3 work in PDAC in China and the recent Breakthrough Therapy Designation for GFH375 in NSCLC, the program clearly aims at building a multi-tumor, multi-geography franchise in KRAS G12D cancers.

From a risk perspective, investors need to keep in mind:

• Efficacy data from the U.S. VS-7375-101 trial are still early and based on small numbers of patients.
• Competition in KRAS G12D is increasing, both from other small molecules and from emerging biologic/neoantigen approaches.
• The regulatory bar for accelerated approvals in solid tumors is higher than it used to be, especially after several withdrawals.

Nonetheless, if safety remains clean at higher doses and the U.S. data reproduce the strength seen in Chinese GFH375 cohorts, VS-7375 has the potential to become a second major value driver alongside the LGSOC franchise.

5. Key risks, retail sentiment and scenario framework

5.1 Main fundamental risks

• Guideline overhang and KRAS wild-type gap. NCCN has not (yet) extended recommendations to KRAS wild-type LGSOC, despite encouraging data and apparent payer flexibility. If this persists, the addressable market could remain more confined than what real-world practice currently suggests.
• Execution risk in launch and prescriber behavior. The early ramp is strong, but sustaining momentum requires consistent engagement with gynecologic oncologists, managing safety in the field and defending reimbursement.
• RAMP 301 and 205 data risk. The mid-2027 topline for RAMP 301 will be the main long-term value inflection. Any signal that efficacy in a broader population is weaker than expected would weigh heavily on the story.
• KRAS G12D competitive landscape. Multiple companies are pursuing inhibitors or combinations in PDAC, NSCLC and CRC. VS-7375 must prove not just “active”, but competitively differentiated.

5.2 Retail sentiment snapshot

Recent discussion among non-professional traders on retail forums (including Reddit-style communities, Stocktwits and X) generally reflects a split picture. On one side, believers focus on the orphan nature of LGSOC, the rapid revenue ramp, the KRAS G12D optionality and the perception that the stock is still under-recognized relative to the clinical story. On the other, more cautious voices point to the size of the current loss, possible future dilution and the long wait until RAMP 301.

As always, this sentiment is highly volatile, based on non-professional opinions and should be treated only as a rough gauge of mood, not as a source of investment insight.

5.3 Scenario framework (qualitative)

A constructive scenario for the next 18–24 months would likely require:

• Sustained quarterly growth in AVMAPKI FAKZYNJA revenue, with deeper penetration in top accounts.
• Reassuring longer-term RAMP 201 and RAMP 201J updates, especially regarding duration of response and wild-type activity.
• Clear, positive signals from disease-specific VS-7375 Phase 2 cohorts in PDAC and NSCLC.

A more cautious scenario would involve slower-than-expected uptake, mixed or inconclusive updates in LGSOC data, or safety/effectiveness concerns emerging in KRAS G12D programs, forcing the company to rethink timelines, spending or the capital structure.

6. Sources (EN)